Search :
Sign in or Register  
Welcome Sign in or Don't have an account?Register

Mouse Anti-MAGEA4 Recombinant Antibody (CBFYM-1311) (CBMAB-M1470-FY)


See all MAGEA4 antibodies
Online Inquiry

Summary

Host Animal
Mouse
Specificity
Human
Clone
CBFYM-1311
Antibody Isotype
IgG2b
Application
WB

Basic Information

Immunogen
Full length human recombinant protein of human MAGEA4(NP_001011550) produced in HEK293T cell
Specificity
Human
Antibody Isotype
IgG2b
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Concentration
2.33 mg/mL
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
MAGE Family Member A4
Introduction
This gene is a member of the MAGEA gene family. The members of this family encode proteins with 50 to 80% sequence identity to each other. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. The MAGEA genes are clustered at chromosomal location Xq28. They have been implicated in some hereditary disorders, such as dyskeratosis congenita. At least four variants encoding the same protein have been found for this gene.
Entrez Gene ID
4103
UniProt ID
P43358
Alternative Names
MAGE Family Member A4; Cancer/Testis Antigen Family 1, Member 4; Melanoma-Associated Antigen 4; Melanoma Antigen Family A4; Cancer/Testis Antigen 1.4; MAGE-41 Antigen; MAGE-X2 Antigen; MAGE-4 Antigen
Function
Regulates cell proliferation through the inhibition of cell cycle arrest at the G1 phase (PubMed:22842486).
Also negatively regulates p53-mediated apoptosis (PubMed:22842486).
Biological Process
Negative regulation of apoptotic processManual Assertion Based On ExperimentIMP:UniProtKB
Negative regulation of transcription by RNA polymerase IIManual Assertion Based On ExperimentIBA:GO_Central
Positive regulation of cell cycleManual Assertion Based On ExperimentIMP:UniProtKB
Cellular Location
Nucleus
More Infomation

Freiberger, S. N., Holzmann, D., Morand, G. B., Hüllner, M., Levesque, M. P., Dummer, R., ... & Rupp, N. J. (2023). Combinational expression of tumor testis antigens NY-ESO-1, MAGE-A3, and MAGE-A4 predicts response to immunotherapy in mucosal melanoma patients. Journal of Cancer Research and Clinical Oncology, 149(9), 5645-5653.

Connacher, R., Avraam, K., Ross, E., Schneck, M., Van Kerckhoven, M., Van Rossom, S., ... & Wang, T. (2023). 198 Development, validation and concordance of two MAGE-A4 immunohistochemistry (IHC) assays to establish prognostic value of MAGE-A4 expression in synovial sarcoma.

Fleming, M. C., Chiou, L. F., Tumbale, P. P., Droby, G. N., Lim, J., Norris-Drouin, J. L., ... & Bowers, A. A. (2022). Discovery and structural basis of the selectivity of potent cyclic peptide inhibitors of MAGE-A4. Journal of medicinal chemistry, 65(10), 7231-7245.

Hashimoto, K., Nishimura, S., Ito, T., Oka, N., Kakinoki, R., & Akagi, M. (2022). Clinicopathological assessment of cancer/testis antigens NY-ESO-1 and MAGE-A4 in osteosarcoma. European Journal of Histochemistry: EJH, 66(3).

Davari, K., Holland, T., Prassmayer, L., Longinotti, G., Ganley, K. P., Pechilis, L. J., ... & Ellinger, C. (2021). Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy. Journal for Immunotherapy of Cancer, 9(3).

Coles, C. H., McMurran, C., Lloyd, A., Hock, M., Hibbert, L., Raman, M. C., ... & Harper, S. (2020). T cell receptor interactions with human leukocyte antigen govern indirect peptide selectivity for the cancer testis antigen MAGE-A4. Journal of Biological Chemistry, 295(33), 11486-11494.

Ishihara, M., Kageyama, S., Miyahara, Y., Ishikawa, T., Ueda, S., Soga, N., ... & Shiku, H. (2020). MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours. BMC cancer, 20(1), 1-8.

Sanderson, J. P., Crowley, D. J., Wiedermann, G. E., Quinn, L. L., Crossland, K. L., Tunbridge, H. M., ... & Gerry, A. B. (2020). Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy. Oncoimmunology, 9(1), 1682381.

Kakimoto, T., Matsumine, A., Kageyama, S., Asanuma, K., Matsubara, T., Nakamura, T., ... & Sudo, A. (2019). Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY‑ESO‑1 and MAGE‑A4 in high‑grade soft‑tissue sarcoma. Oncology Letters, 17(4), 3937-3943.

Van Tine, B. A., Butler, M. O., Araujo, D., Johnson, M. L., Clarke, J., Liebner, D., ... & Hong, D. S. (2019). ADP-A2M4 (MAGE-A4) in patients with synovial sarcoma. Annals of Oncology, 30, v684-v685.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-MAGEA4 Recombinant Antibody (CBFYM-1311)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Learn more

Documents

Request bulk or custom quoteOnline Inquiry
Second antibody and isotype control

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Online Inquiry